Surgery Partners, Inc. 10-Q

Item 1. Financial Statements SURGERY PARTNERS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in millions, except per share amounts) (Unaudited) March 31, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 229.3 $ 269.5 Accounts receivable 570.6 579.1 Inventories 88.1 88.4 Prepaid expenses 36.3 36.4 Other current assets 150.3 146.0 Total current assets 1,074.6 1,119.4 Property and equipment, net of accumulated depreciation of $ 587.0 and $ 553.9 , respectively 1,151.1 1,088.3 Goodwill and other intangible assets, net 5,171.4 5,113.7 Investments in and advances to affiliates 218.6 215.4 Right-of-use operating lease assets 277.7 295.7 Other long-term assets 55.8 57.5 Total assets $ 7,949.2 $ 7,890.0 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 165.0 $ 208.7 Accrued payroll and benefits 67.0 60.4 Other current liabilities 233.5 253.9 Current maturities of long-term debt 103.9 101.4 Total current liabilities 569.4 624.4 Long-term debt, less current maturities 3,446.9 3,268.9 Right-of-use operating lease liabilities 272.9 292.1 Long-term deferred tax liabilities 38.9 39.2 Other long-term liabilities 34.6 30.2 Non-controlling interests—redeemable 430.5 438.8 Stockholders' equity: Preferred stock, $ 0.01 par value; shares authorized - 20,310,000 ; shares issued or outstanding - none — — Common stock, $ 0.01 par value; shares authorized - 300,000,000 ; shares issued and outstanding - 128,192,739 and 127,109,383 , respectively 1.3 1.3 Additional paid-in capital 2,525.9 2,520.9 Accumulated other comprehensive (loss) income ( 11.8 ) 4.8 Retained deficit ( 775.0 ) ( 737.3 ) Total Surgery Partners, Inc. stockholders' equity 1,740.4 1,789.7 Non-controlling interests—non-redeemable 1,415.6 1,406.7 Total stockholders' equity 3,156.0 3,196.4 Total liabilities and stockholders' equity $ 7,949.2 $ 7,890.0 See notes to unaudited condensed consolidated financial statements. 1 Table of Contents SURGERY PARTNERS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, dollars in millions, except per share amounts; shares in thousands) Three Months Ended March 31, 2025 2024 Revenues $ 776.0 $ 717.4 Operating expenses: Salaries and benefits 238.6 215.2 Supplies 215.8 188.8 Professional and medical fees 95.3 82.6 Lease expense 20.8 21.4 Other operating expenses 43.6 54.1 Cost of revenues 614.1 562.1 General and administrative expenses 36.0 33.2 Depreciation and amortization 36.3 33.7 Transaction and integration costs 24.7 17.4 Net loss on disposals, consolidations and deconsolidations 6.4 1.5 Equity in earnings of unconsolidated affiliates ( 5.6 ) ( 2.7 ) Litigation settlements 2.2 ( 1.8 ) Other income, net — ( 2.0 ) 714.1 641.4 Operating income 61.9 76.0 Interest expense, net ( 62.2 ) ( 47.3 ) (Loss) income before income taxes ( 0.3 ) 28.7 Income tax expense — ( 4.4 ) Net (loss) income ( 0.3 ) 24.3 Less: Net income attributable to non-controlling interests ( 37.4 ) ( 36.7 ) Net loss attributable to Surgery Partners, Inc. $ ( 37.7 ) $ ( 12.4 ) Net loss per share attributable to common stockholders: Basic $ ( 0.30 ) $ ( 0.10 ) Diluted (1) $ ( 0.30 ) $ ( 0.10 ) Weighted average common shares outstanding: Basic 126,602 125,972 Diluted (1) 126,602 125,972 (1) The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive. See notes to unaudited condensed consolidated financial statements. 2 Table of Contents SURGERY PARTNERS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited, dollars in millions) Three Months Ended March 31, 2025 2024 Net (loss) income $ ( 0.3 ) $ 24.3 Other comprehensive (loss) income, net of tax: Derivative activity, net of tax of $ 0 ( 16.6 ) ( 5.5 ) Comprehensive (loss) income ( 16.9 ) 18.8 Less: Comprehensive income attributable to non-controlling interests ( 37.4 ) ( 36.7 ) Comprehensive loss attributable to Surgery Partners, Inc. $ ( 54.3 ) $ ( 17.9 ) See notes to unaudited condensed consolidated financial statements. 3 Table of Contents SURGERY PARTNERS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited, dollars in millions, shares in thousands) Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Retained Deficit Non-Controlling Interests— Non-Redeemable Total Shares Amount Balance as of December 31, 2024 127,109 $ 1.3 $ 2,520.9 $ 4.8 $ ( 737.3 ) $ 1,406.7 $ 3,196.4 Net (loss) income — — — — ( 37.7 ) 32.6 ( 5.1 ) Equity-based compensation 1,084 — 7.6 — — — 7.6 Other comprehensive loss — — — ( 16.6 ) — — ( 16.6 ) Acquisition and disposal of shares of non-controlling interests, net — — ( 2.6 ) — — 25.6 23.0 Distributions to non-controlling interests—non-redeemable holders — — — — — ( 49.3 ) ( 49.3 ) Balance as of March 31, 2025 128,193 $ 1.3 $ 2,525.9 $ ( 11.8 ) $ ( 775.0 ) $ 1,415.6 $ 3,156.0 Balance as of December 31, 2023 126,594 $ 1.3 $ 2,497.6 $ 57.5 $ ( 569.2 ) $ 1,047.3 $ 3,034.5 Net (loss) income — — — — ( 12.4 ) 29.3 16.9 Equity-based compensation 508 — 4.9 — — — 4.9 Other comprehensive loss — — — ( 5.5 ) — — ( 5.5 ) Acquisition and disposal of shares of non-controlling interests, net — — ( 6.9 ) — — 23.7 16.8 Distributions to non-controlling interests—non-redeemable holders — — — — — ( 29.7 ) ( 29.7 ) Balance as of March 31, 2024 127,102 $ 1.3 $ 2,495.6 $ 52.0 $ ( 581.6 ) $ 1,070.6 $ 3,037.9 See notes to unaudited condensed consolidated financial statements. 4 Table of Contents SURGERY PARTNERS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, dollars in millions) Three Months Ended March 31, 2025 2024 Cash flows from operating activities: Net (loss) income $ ( 0.3 ) $ 24.3 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 36.3 33.7 Non-cash lease expense 9.6 9.0 Non-cash interest expense, net 2.5 1.5 Equity-based compensation expense 7.6 4.9 Net loss on disposals, consolidations and deconsolidations 6.4 1.5 Deferred income taxes ( 0.3 ) 2.5 Equity in earnings of unconsolidated affiliates, net of distributions received 1.1 1.0 Changes in operating assets and liabilities, net of acquisitions and divestitures: Accounts receivable 4.8 5.4 Other operating assets and liabilities ( 61.7 ) ( 43.1 ) Net cash provided by operating activities 6.0 40.7 Cash flows from investing activities: Purchases of property and equipment ( 22.7 ) ( 21.0 ) Payments for acquisitions, net of cash acquired ( 44.0 ) ( 54.6 ) Proceeds from disposals of facilities and other assets 4.8 1.5 Purchases of equity investments ( 3.8 ) ( 2.0 ) Other investing activities ( 10.7 ) ( 7.0 ) Net cash used in investing activities ( 76.4 ) ( 83.1 ) Cash flows from financing activities: Principal payments on long-term debt ( 119.3 ) ( 120.2 ) Borrowings of long-term debt 213.6 192.5 Distributions to non-controlling interest holders ( 62.3 ) ( 40.5 ) Proceeds related to ownership transactions with non-controlling interest holders 1.7 1.4 Other financing activities ( 3.5 ) ( 1.5 ) Net cash provided by financing activities 30.2 31.7 Net decrease in cash and cash equivalents ( 40.2 ) ( 10.7 ) Cash and cash equivalents at beginning of period 269.5 195.9 Cash and cash equivalents at end of period $ 229.3 $ 185.2 See notes to unaudited condensed consolidated financial statements. 5 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1. Organization and Summary of Accounting Policies Organization Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, gastroenterology, ophthalmology, and general surgery. Although some of the Company's surgical hospitals may include emergency departments, they are generally not equipped to handle a broad spectrum of patient needs, including critical and traumatic injuries. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company." As of March 31, 2025, the Company owned or operated a portfolio of 164 surgical facilities, comprised of 145 ASCs and 19 surgical hospitals in 30 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves. The Company owned a majority interest in 83 of these surgical facilities and consolidated 118 surgical facilities for financial reporting purposes. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Annual Report on Form 10-K"). Certain prior year amounts have been reclassified to conform with the current year presentation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates. Revenues The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The following table presents a summary of revenues by service type as a percentage of total revenues: Three Months Ended March 31, 2025 2024 Patient service revenues 97.8 % 98.3 % Other service revenues 2.2 % 1.7 % Total revenues 100.0 % 100.0 % 6 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Patient service revenues. This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient’s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. Because the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service. The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and implicit price concessions. The Company estimates its contractual adjustments and implicit price concessions based on contractual agreements, its discount policies and historical experience of cash collections and historical write-offs. Contractual allowances are recorded at the time of payment and the time of billing for surgical hospitals and ASCs, respectively. Changes in estimated contractual adjustments and discounts are recorded in the period of change. Several states utilize supplemental Medicaid reimbursement programs for the purpose of providing reimbursement to providers to increase base rates to the levels that Medicare would have paid for the same service or for payments that offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (“CMS”) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. We account for payments under these supplemental programs as variable consideration and estimate the amount using the most likely amount method. Reimbursement under these programs, including the recognition of variable consideration, is reflected in patient service revenues. Taxes or other program-related costs are reflected in other operating expenses. Other service revenues. Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed. The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions): Three Months Ended March 31, 2025 2024 Amount % Amount % Patient service revenues: Private insurance $ 406.4 53.6 % $ 361.0 51.2 % Government 316.2 41.7 % 303.6 43.0 % Self-pay 19.8 2.6 % 19.8 2.8 % Other (1) 16.0 2.1 % 20.9 3.0 % Total patient service revenues 758.4 100.0 % 705.3 100.0 % Other service revenues 17.6 12.1 Total revenues $ 776.0 $ 717.4 (1) Other is comprised of automobile liability, letters of protection and other payor types. Accounts Receivable Accounts receivable from third-party payors are recorded net of contractual allowances and implicit price concessions, which are estimated based on established fee schedules, relationships with payors, procedure statistics and other objective information including the historical trend of cash collections and contractual write-offs. Contractual allowances are recorded at the time of payment and the time of billing for surgical hospitals and ASCs, respectively. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are 7 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient’s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients. The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required. Income Taxes We use the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. We assess the likelihood that deferred tax assets will be recovered from sources of future taxable income. To the extent we believe that recovery is not probable, a valuation allowance is established. To the extent we establish a valuation allowance or subsequently increase or decrease this allowance, we must include an adjustment as part of the income tax provision in our results of operations. The first step in determining the deferred tax asset valuation allowance is identifying reporting jurisdictions where we have a history of tax and operating losses or are projected to have losses in future periods as a result of changes in operational performance. We then determine if a valuation allowance should be established against the deferred tax assets for that reporting jurisdiction. The second step is to determine the amount of the valuation allowance. We will generally establish a valuation allowance equal to the net deferred tax asset (deferred tax assets less deferred tax liabilities) related to the jurisdiction identified in step one of the analysis. In certain cases, we may not reduce the valuation allowance by the amount of the deferred tax liabilities depending on the nature and timing of future taxable income attributable to deferred tax liabilities. In assessing tax contingencies, we apply the provisions of ASC 740, “Income Taxes”. We apply the recognition threshold and measurement of a tax position taken or expected to be taken in a tax return and follow the guidance on various matters such as derecognition, interest, penalties and disclosure. We classify interest and penalties as a component of income tax expense. During each reporting period, we assess the facts and circumstances related to recorded tax contingencies, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue. If tax contingencies are no longer deemed probable based upon new facts and circumstances, the contingency is reflected as a reduction of the provision for income taxes in the current period. For the three months ended March 31, 2025, the Company estimated its effective tax rate under a discrete-period calculation based solely on its income from operations for the three months ended March 31, 2025. The Company's effective tax rate was 0 % for the three months ended March 31, 2025. For the three months ended March 31, 2025, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company’s valuation allowance attributable to interest expense limitations, and a permanent difference between the book and tax deductions related to the Company’s stock compensation expense. For the three months ended March 31, 2024, the Company estimated its effective tax rate under the annual effective tax rate approach. The Company’s effective tax rate was 15.3 % for the three months ended March 31, 2024. For the three months ended March 31, 2024, the effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company’s valuation allowance attributable to interest expense limitations, state tax expense, and a discrete tax expense of $ 0.7 million related to the vesting of restricted stock awards. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period. Goodwill Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions, disposals and deconsolidations for the three months ended March 31, 2025 is included in Note 2. "Acquisitions, Disposals and Deconsolidations." 8 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) A summary of activity related to goodwill for the three months ended March 31, 2025 is as follows (in millions): Balance as of December 31, 2024 $ 5,068.0 Acquisitions, including post acquisition adjustments 69.6 Disposals ( 11.4 ) Balance as of March 31, 2025 $ 5,126.2 A detailed evaluation of potential impairment indicators was performed as of March 31, 2025, which specifically considered recent changes in interest rates, inflation risk and market volatility. On the basis of available evidence as of March 31, 2025, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company’s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future. Derivative Instruments and Hedging Activities The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting. The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio. Non-Controlling Interests—Redeemable Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners’ or physician minority members’, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. Management believes the likelihood of an event occurring that would trigger such purchases was remote as of March 31, 2025. The non-controlling interests — redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets. A summary of activity related to redeemable non-controlling interests is as follows (in millions): Three Months Ended March 31, 2025 2024 Balance at beginning of period $ 438.8 $ 327.4 Net income attributable to non-controlling interests—redeemable 4.8 7.4 Acquisition and disposal of shares of non-controlling interests, net—redeemable 1.0 ( 0.3 ) Distributions to non-controlling interest —redeemable holders ( 14.1 ) ( 10.8 ) Balance at end of period $ 430.5 $ 323.7 Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy: • Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. 9 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued. A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions): Carrying Amount Fair Value March 31, 2025 December 31, 2024 March 31, 2025 December 31, 2024 Senior secured term loan $ 1,384.6 $ 1,388.1 $ 1,381.1 $ 1,400.2 7.250 % senior unsecured notes due 2032 $ 800.0 $ 800.0 $ 790.0 $ 815.0 The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values. Variable Interest Entities The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, " Consolidation ." The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of March 31, 2025, the Company's consolidated VIEs consisted of nine surgical facilities and 28 physician practices. The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of March 31, 2025 and December 31, 2024, were $ 76.7 million and $ 87.0 million, respectively, and the total liabilities of the consolidated VIEs were $ 42.8 million and $ 55.0 million, respectively. Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures , which establishes new requirements for the categorization and disaggregation of information in the rate reconciliation as well as for disaggregation of income taxes paid. The ASU is effective for annual periods beginning after December 15, 2024 and interim periods beginning after December 15, 2025. The amendments in this ASU may be applied prospectively or retrospectively to all periods presented and early adoption is permitted. The Company is planning to adopt during the year ended December 31, 2025. 2. Acquisitions, Disposals and Deconsolidations Acquisitions During the three months ended March 31, 2025: • The Company acquired a controlling interest in four surgical facilities and one physician practice for aggregate cash consideration of $ 44.0 million, net of cash acquired. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $ 28.0 million and goodwill of $ 70.2 million. • The Company acquired non-controlling interests in one surgical facility and for aggregate cash consideration of $ 3.8 million. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the condensed consolidated balance sheets. During the three months ended March 31, 2024: • The Company acquired a controlling interest in two surgical facilities and several physician practices for aggregate cash consideration of $ 66.0 million, net of cash acquired, and non-cash consideration of $ 1.1 million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. As of March 31, 2024, $ 11.4 million of the cash consideration was deferred and included as a component of current liabilities in the condensed consolidated balance sheets. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $ 21.2 million and goodwill of $ 77.2 million. 10 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Disposals and Deconsolidations During the three months ended March 31, 2025: • The Company sold a portion of its interests in one surgical facility for net cash proceeds of $ 0.5 million. As a result of the transaction, the Company no longer controlled the previously controlled surgical facility but retained a non-controlling interest, resulting in the deconsolidation of the previously consolidated entity. This transaction resulted in a pretax net loss on deconsolidation of $ 3.0 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2025. The net gain was determined based on the difference between the net cash proceeds plus the fair value of the Company’s retained interests in the entity and the carrying values of both the tangible and intangible assets of the entity immediately prior to the transaction. • The Company sold or otherwise disposed of its controlling interests in two surgical facilities for aggregate net cash proceeds of $ 4.3 million. In connection with the transactions, the Company recognized a pre-tax net gain of $ 0.5 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2025. During the three months ended March 31, 2024: • The Company sold a portion of its interests in a surgical facility for net cash proceeds of $ 1.5 million. As a result of the transaction, the Company lost control of the previously controlled surgical facility but retains a non-controlling interest, resulting in the deconsolidation of the previously consolidated entity. This transaction resulted in a pretax net gain on deconsolidation of $ 2.7 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2024. The net loss was determined based on the difference between the net cash proceeds plus the fair value of the Company’s retained interests in the entity and the carrying values of both the tangible and intangible assets of the entity immediately prior to the transaction. 3. Long-Term Debt A summary of long-term debt follows (in millions): March 31, 2025 December 31, 2024 Senior secured term loan (1) $ 1,384.6 $ 1,388.1 Senior secured revolving credit facility 304.0 192.0 7.250 % senior unsecured notes due 2032 800.0 800.0 Notes payable and other secured loans 227.5 224.4 Finance lease obligations 866.6 798.7 Less: unamortized debt issuance costs and discounts ( 31.9 ) ( 32.9 ) Total debt 3,550.8 3,370.3 Less: current maturities 103.9 101.4 Total long-term debt $ 3,446.9 $ 3,268.9 (1) Includes unamortized fair value discount of $ 1.4 million as of March 31, 2025 and December 31, 2024. Revolving Credit Facility As of March 31, 2025, the Company's availability on its $ 703.8 million senior secured revolving credit facility (the "Revolver") was $ 388.9 million (including letters of credit of $ 10.9 million). The increase in outstanding borrowings on the Revolver compared to December 31, 2024 was primarily due to the timing of acquisitions. 4. Leases The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. 11 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the condensed consolidated balance sheets (in millions): Classification in Condensed Consolidated Balance Sheets March 31, 2025 December 31, 2024 Assets: Operating lease assets Right-of-use operating lease assets $ 277.7 $ 295.7 Finance lease assets Property and equipment, net of accumulated depreciation 716.8 655.6 Total leased assets $ 994.5 $ 951.3 Liabilities: Operating lease liabilities: Current Other current liabilities $ 39.6 $ 41.0 Long-term Right-of-use operating lease liabilities 272.9 292.1 Total operating lease liabilities 312.5 333.1 Finance lease liabilities: Current Current maturities of long-term debt 34.3 33.1 Long-term Long-term debt, less current maturities 832.3 765.6 Total finance lease liabilities 866.6 798.7 Total lease liabilities $ 1,179.1 $ 1,131.8 The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statements of operations (in millions): Three Months Ended March 31, 2025 2024 Operating lease costs $ 16.5 $ 15.9 Finance lease costs: Amortization of leased assets 16.0 11.8 Interest on lease liabilities 18.2 13.0 Total finance lease costs 34.2 24.8 Variable and short-term lease costs 4.6 5.8 Total lease costs $ 55.3 $ 46.5 The following table presents supplemental cash flow information (in millions): Three Months Ended March 31, 2025 2024 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 15.8 $ 15.6 Operating cash outflows from finance leases 16.7 12.4 Financing cash outflows from finance leases 6.2 7.5 Right-of-use assets obtained in exchange for lease obligations: Operating leases 10.8 19.2 Finance leases 60.0 12.1 12 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 5. Derivatives and Hedging Activities The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2025 and 2024, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt. The key terms of interest rate swaps and interest rate caps outstanding are presented below: March 31, 2025 December 31, 2024 Description Effective Date Notional Amount (in millions) Status Notional Amount (in millions) Status Maturity Date Pay-fixed swap May 7, 2021 $ — Matured $ 435.0 Active March 31, 2025 Pay-fixed swap May 7, 2021 — Matured 330.0 Active March 31, 2025 Pay-fixed swap May 7, 2021 — Matured 435.0 Active March 31, 2025 Interest rate cap September 30, 2021 — Matured 143.6 Active March 31, 2025 Interest rate cap September 30, 2021 — Matured 8.2 Active March 31, 2025 Deferred premium cap March 31, 2025 396.0 Active 396.0 Active December 31, 2028 Deferred premium cap March 31, 2025 198.0 Active 198.0 Active December 31, 2028 Deferred premium cap March 31, 2025 396.0 Active 396.0 Active December 31, 2028 Deferred premium cap March 31, 2025 198.0 Active 198.0 Active December 31, 2028 Deferred premium cap March 31, 2025 198.0 Active 198.0 Active December 31, 2028 $ 1,386.0 $ 2,737.8 During the three months ended March 31, 2025, the Company had three interest rate swaps designated in cash flow hedging relationships, which matured on March 31, 2025. Prior to maturity, the interest rate swaps had a total notional amount of $ 1.2 billion and were pay-fixed, received 1-Month SOFR (subject to a minimum of 0.75 %). During the three months ended March 31, 2025, the Company had two interest rate caps designated in cash flow hedging relationships, which matured on March 31, 2025. Prior to maturity, the interest caps had a total notional amount of $ 151.8 million. Effective March 31, 2025, the Company had five deferred premium interest rate cap agreements. The deferred premium interest rate caps are designated in cash flow hedging relationships with a total notional amount of $ 1.4 billion. These financial instruments are designed to limit the Company's interest rate exposure on its term loan concurrent with the positions that matured on March 31, 2025. Prior to maturity, the pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps were considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. Within the Company’s condensed consolidated balance sheets, the financing elements treated as debt instruments were carried at amortized cost and the embedded at-market derivatives were recorded at fair value. The fair value was determined using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portions that were treated as an at-market derivative are classified as operating activities. Within the Company’s condensed consolidated balance sheets, the interest rate caps are recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the condensed consolidated statements of cash flows. The fair value of the interest rate caps is determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy. For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company’s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. Over the next 12 months, the Company estimates that an additional $ 5.6 million will be reclassified as a increase to interest expense. 13 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions): March 31, 2025 December 31, 2024 Assets Liabilities Assets Liabilities Derivatives in cash flow hedging relationships Interest rate caps (1) $ — $ — $ 1.1 $ — Interest rate swaps (1) — — 9.7 — Interest rate caps (2) — 11.8 — 6.1 Interest rate swaps (3) (4) — — — 3.5 Total $ — $ 11.8 $ 10.8 $ 9.6 (1) Amounts were included in other current assets on the condensed consolidated balance sheets as of December 31, 2024. (2) Amounts were included in other long-term liabilities on the condensed consolidated balance sheets as of December 31, 2024. (3) Amounts were included in other current liabilities on the condensed consolidated balance sheets as of March 31, 2025 and December 31, 2024. (4) Amounts related to the financing component of the pay-fixed interest rate swaps. The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statements of operations (in millions): Three Months Ended March 31, Location 2025 2024 Derivatives in cash flow hedging relationships Gain (loss) recognized in OCI (effective portion) $ ( 5.6 ) $ 9.2 Gain reclassified from accumulated OCI into income (effective portion) Interest expense, net $ ( 11.0 ) $ ( 14.7 ) 6. Earnings Per Share Basic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share. A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands): Three Months Ended March 31, 2025 2024 Numerator: Net loss attributable to Surgery Partners, Inc. $ ( 37.7 ) $ ( 12.4 ) Denominator: Weighted average common shares outstanding: Basic 126,602 125,972 Diluted (1) 126,602 125,972 Net loss per share attributable to common stockholders: Basic $ ( 0.30 ) $ ( 0.10 ) Diluted (1) $ ( 0.30 ) $ ( 0.10 ) Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive: Stock options 957 1,237 Restricted shares 138 148 (1) The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive. 14 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 7. Other Current Liabilities A summary of other current liabilities was as follows (in millions): March 31, 2025 December 31, 2024 Right-of-use operating lease liabilities $ 39.6 $ 41.0 Cost report liabilities 20.7 21.3 Amounts due to patients and payors 38.6 31.8 Interest payable 28.1 13.4 Interest rate swaps — 3.5 Accrued expenses and other 106.5 142.9 Total $ 233.5 $ 253.9 8. Commitments and Contingencies Professional, General and Workers' Compensation and Cyber Liability Risks The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation and cyber liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of March 31, 2025 and December 31, 2024 were $ 19.7 million and $ 19.2 million, respectively. Expected insurance recoveries of $ 9.6 million as of both March 31, 2025 and December 31, 2024 are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. 9. Segment Reporting Segment information is prepared on the same basis that our CEO, who is our Chief Operating Decision Maker ("CODM"), manages our segments, evaluates financial results, and makes key operating decisions. We have one reportable segment: Surgical Facilities. The Surgical Facilities reportable segment is comprised of two operating segments, which we have aggregated to a single reportable segment in consideration of the aggregation criteria set forth in ASC 280. The Surgical Facilities reportable segment includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues primarily from contracts with patients in which the performance obligations are to provide health care services. The "All other" line item primarily consists of amounts attributable to the Company's corporate general and administrative functions. The Company defines its segment on the basis of the way in which its internally reported financial information is regularly reviewed by the CODM to assess performance and allocate resources. During the three months ended March 31, 2025, the operating segment previously defined as "Ancillary services" was included with Surgical Facilities based on changes in the operational management of our multi-specialty physician practices. Accordingly, the Company has reclassified segment disclosures previously reported to conform to current year presentation. The Company’s CODM uses Adjusted EBITDA to assess performance and allocate resources. The CODM considers budget-to-actual and actual versus prior period variances on a periodic basis as a means of assessing performance. The following segment information, including significant segment expenses, is presented in millions: 15 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Three Months Ended March 31, 2025 2024 Surgical Facilities Revenues $ 776.0 $ 717.4 Less: Salaries and benefits 238.6 215.2 Supplies 215.8 188.8 Professional and medical fees 95.3 82.6 Lease expense 20.8 21.4 Equity in earnings of unconsolidated affiliates ( 5.6 ) ( 2.7 ) Net income attributable to non-controlling interests 37.4 36.7 Other segment expense, net 41.7 50.1 644.0 592.1 Adjusted Surgical Facilities EBITDA $ 132.0 $ 125.3 Reconciliation: Add back: Net income attributable to non-controlling interests ( 37.4 ) ( 36.7 ) Corporate and other unallocated expenses (1) 71.2 52.3 Depreciation and amortization 36.3 33.7 Interest expense, net 62.2 47.3 (Loss) income before income taxes $ ( 0.3 ) $ 28.7 (1) Corporate and other unallocated expenses represent corporate overhead expenses that have not been allocated to any segment for reporting purposes including general and administrative expenses, transaction and integration costs, net loss on disposals, consolidations and deconsolidations, litigation settlements, and loss on debt extinguishment. Three Months Ended March 31, 2025 2024 Depreciation and amortization: Surgical Facilities $ 33.8 $ 31.5 All other 2.5 2.2 Total depreciation and amortization expense $ 36.3 $ 33.7 March 31, 2025 December 31, 2024 Assets: Surgical Facilities $ 7,532.3 $ 7,466.3 All other 416.9 423.7 Total assets $ 7,949.2 $ 7,890.0 Three Months Ended March 31, 2025 2024 Cash purchases of property and equipment: Surgical Facilities $ 21.8 $ 16.3 All other 0.9 4.7 Total cash purchases of property and equipment $ 22.7 $ 21.0 16 Table of Contents